Drug and Alcohol Dependence
Volume 121, Issue 1 , Pages 1-9 , 1 February 2012

MDMA and temperature: A review of the thermal effects of ‘Ecstasy’ in humans

  • A.C. Parrott

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 1792 295271; fax: +44 1792 295679.

Received 9 June 2011 ,Revised 20 July 2011 ,Accepted 12 August 2011.

References 

  1. Banks ML, Sprague JE, Czoty PW, Nader MA. Effects of ambient temperature on the relative reinforcing strength of MDMA using a choice procedure in monkeys. Psychopharmacology. 2008;196:63–70
  2. Bedi G, Redman J. Recreational ecstasy use: acute effects potentiated by ambient conditions?. Neuropsychobiology. 2006;53:113
  3. Benemar K, Geller EB, Adler MW. A new brain area affected by 3,4-methylenedioxymethamphetamine: a microdialysis-biotelemetry study. Eur. J. Pharmacol. 2008;596:84–88
  4. Brown PL, Kiyatkin EA. Brain hyperthermia induced by MDMA (‘ecstasy’): modulation by environmental conditions. Eur. J. Neurosci. 2004;20:51–58
  5. Brown C, Osterloh J. Multiple severe complications from recreational ingestion of MDMA (’Ecstasy’). JAMA. 1987;258:780–781
  6. Chadwick IS, Curry PD, Linsley A, Freemont AJ, Doran B. Ecstasy, 3,4-methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia. J. Royal Soc. Med. 1991;84:371
  7. Cohen RS. Subjective reports on the effects of the MDMA (Ecstasy) experience in humans. Prog. Neuropsychopharmacol. Biol. Psychiatry. 1995;19:1137–1145
  8. Cornish JL, Schahnawaz Z, Thompson MR, Wong S, Morley KC, Hunt GE, et al. Heat increases 3,4-methylenedioxymethamphetamine administration and social effects in rats. Eur. J. Pharmacol. 2003;482:339–341
  9. Corre JR. A fatal trip with ecstasy: a case of 3,4-methylenedioxymethamphetamine toxicity. J. Royal Soc. Med. 1996;89:51–52
  10. Dafters R. Hyperthermia following MDMA administration in rats: effects of ambient temperature, water consumption, and chronic dosing. Physiol. Behav. 1995;58:877–882
  11. Davison D, Parrott AC. Ecstasy in recreational users: self-reported psychological and physiological effects. Hum. Psychopharmacol. 1997;12:91–97
  12. Farre M, Abanades S, Roset PN, Peiro AM, Torrens M, O’Mathuna B, et al. Pharmacological interactions between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacodynamics. J. Pharmacol. Exp. Ther. 2007;323:954–962
  13. Folkard S. Diurnal Variation. Stress and Fatigue in Human Performance. Chichester and New York: Wiley; 1983;
  14. Freedman RR, Johanson CE, Tancer ME. Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology. 2005;183:248–256
  15. Gordon CJ. Thermophysiological response to hyperthermic drugs: extrapolating from rodent to human. Prog. Brain Res. 2007;162:63–79
  16. Gordon CJ, Watkinson WP, O’Callaghan JP, Miller DB. Effects of 3,4-methylenedioxymethamphetamine on thermoregulatory responses in the rat. Pharmacol. Biochem. Behav. 1991;38:339–344
  17. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol. Rev. 2003;55:463–508
  18. Green AR, Sanchez V, O'Shea E, Saadat KS, Elliott JM, Colado MI. Effect of ambient temperature and a prior neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA) on the hyperthermic response of rats to a single or repeated (‘binge’ ingestion) low dose of MDMA. Psychopharmacology. 2004;173:264–269
  19. Greene SL, Wood DM, Dargan PI. Epidemiological and clinical characteristics of acute MDMA related presentations to an inner city London Emergency Department. Neuropsychobiology. 2009;60:214
  20. Grob CS, Poland RE, Chang L, Ernst T. Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav. Brain. Res. 1996;73:103–107
  21. Grunau BE, Wiens MO, Brubacher JR. Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review. CJEM. 2010;12:435–442
  22. Hall AP, Henry JA. Acute toxicity of ‘Ecstasy’ (MDMA) and related compounds: overview of pathophysiology and clinical management. Br. J. Anaesth. 2005;96:678–685
  23. Halpern P, Moskovich J, Avrahami B, Bentur Y, Soffer D, Peleg K. Morbidity associated with MDMA (ecstasy) abuse—a survey of emergency department admissions. Hum. Exp. Toxicol. 2011;30:259–266
  24. Harris DS, Baggott M, Mendelson JH, Mendelson JE, Jones RT. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology. 2002;162:396–405
  25. Henry JA, Jeffries KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine (“Ecstasy”). Lancet. 1992;340:384–387
  26. Huether G, Zhou D, Ryuther E. Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) and its congeners. J. Neural Transm. 1997;104:771–794
  27. Irvine RJ, Keane M, Felgate P, Mc Cann UD, Callaghan PD, White JM. Plasma drug concentrations and physiological measures in dance party participants. Neuropsychopharmacology. 2006;31:424–430
  28. Kish SJ, Lerch J, Furukawa Y, Tong J, Mc Cluskey T, Wilkins D, et al. Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study. Brain. 2010;133:1779–1797
  29. Kiyatkin EA. Brian hyperthermia during physiological and pathological conditions: causes, mechanisms, and functional implications. Curr. Neurovasc. Res. 2004;1:77–90
  30. Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huetis MA. Physiological and subjective responses to 3,4-methylenedioxymethamphetamine administration. J. Clin. Psychopharmacol. 2008;28:432–440
  31. Leon LR. Thermoregulatory responses to environmental toxicants: the interactions of thermal stress and toxicant exposure. Toxicol. App. Pharmacol. 2008;233:146–161
  32. Liechti ME, Vollenweider FX. The serotonin uptake inhibitor citalopram reduces cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine (ecstasy) in human volunteers. J. Psychopharmacol. 2000;14:269–274
  33. Liechti ME, Saur WR, Gamma A, Hell D, Vollenweider FX. Psychological and physiological effects of MDMA (ecstasy) after pretreatment with the 5-HT2 antagonist ketanserin in healthy humans. Neuropsychopharmacology. 2000;23:396–404
  34. Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective effects of MDMA. Psychopharmacology. 2001;154:161–168
  35. Malberg JE, Seiden LS. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J. Neurosci. 1998;18:5086–5094
  36. Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J, et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J. Pharmacol. Exp. Ther. 1999;290:136–145
  37. Mills EM, Rusyniak DE, Sprague JE. The role of the sympathetic nervous system and uncoupling proteins in the thermogenesis induced by 3,4-methylenedioxymethamphetamine. J. Mol. Med. 2004;82:787–799
  38. Morefield KM, Keane M, Felgate P, White JM, Irvine RJ. The acute psychobiological impacts of ilicit 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) consumption in recreational environments. Neuropsychobiology. 2009;60:216
  39. Morris D. The Naked Ape. London: Corgi Press; 1967;
  40. Olausson H, Charron J, Marchand S, Villemure C, Strigo IA, Bushnell MC. Feelings of warmth correlate with neural activity in right anterior insular cortex. Neurosci. Lett. 2005;389:1–5
  41. Parrott AC. Human psychopharmacology of ecstasy (MDMA): a review of fifteen years of empirical research. Hum. Psychopharmacol. 2001;16:557–577
  42. Parrott AC. Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol. Biochem. Behav. 2002;71:837–844
  43. Parrott AC. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, dosage levels, and the changing perceptions of purity. Psychopharmacology. 2004;173:234–241
  44. Parrott AC. MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy: the neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology. 2004;50:329–335
  45. Parrott AC. Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy. J. Psychopharmacol. 2005;19:71–83
  46. Parrott AC. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational Ecstasy users, the integrative role of bio-energetic stress. J. Psychopharmacol. 2006;20:147–163
  47. Parrott AC. Cortisol and MDMA (3,4-methylenedioxymethamphetamine): neurohormonal aspects of bioenergetic-stress in Ecstasy users. Neuropsychobiology. 2009;60:148–158
  48. Parrott AC, Young L. Increased body temperature in recreational Ecstasy/MDMA users out clubbing and dancing. J. Psychopharmacol. 2005;19:a26
  49. Parrott AC, Rodgers J, Buchanan T, Ling J, Heffernan T, Scholey AB. Dancing hot on ecstasy: physical activity and thermal comfort ratings are associated with the memory and other psychobiological problems of recreational MDMA users. Hum. Psychopharmacol. 2006;21:285–298
  50. Parrott AC, Milani RM, Gouzoulis-Mayfrank E, Daumann J. Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users. J. Neural Transm. 2007;114:959–968
  51. Parrott AC, Adnum L, Evans A, Kissling C, Thome J. Heavy Ecstasy/MDMA use at cool house parties: substantial cortisol release and increased body temperature. J. Psychopharmacol. 2007;21:a35
  52. Parrott AC, Lock J, Conner AC, Kissling C, Thome J. Dance clubbing on MDMA and during abstinence from Ecstasy/MDMA: prospective neuroendocrine and psychobiological changes. Neuropsychobiology. 2008;57:165–180
  53. Patel MM, Belson MG, Longwater AB, Olson KR, Miller MA. Methylenedioxymethamphetamine (ecstasy)-related hyperthermia. J. Emerg. Med. 2005;29:451–454
  54. Peroutka SJ, Newman H, Harris H. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology. 1988;1:273–277
  55. Rusniak DE, Sprague JE. Toxin-induced hyperthermic syndromes. Med. Clin. North Am. 2005;89:1277–1296
  56. Schifano F, Corkery J, Deluca P, Oyefeso A, Ghodse AH. Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994–2003). J. Psychopharmacol. 2006;20:456–463
  57. Shulgin AT. The background and chemistry of MDMA. J. Psychoactive Drugs. 1986;18:291–304
  58. Sprague JE, Mallett NM, Rusniak DE, Mills E. Hypothalamic-pituitary-thyroid axis and sympathetic nervous system involvement in hyperthermia induced by 3,4-methylenedioxymethamphetamine (Ecstasy). J. Pharmacol. Exp. Ther. 2003;305:159–166
  59. Sprague JE, Yang X, Sommers J, Gilman TL, Mills EM. Roles of norepinephrine, free fatty acids, thyroid status, and skeletal muscle uncoupling protein 3 expression in sympathomimetic-induced thermogenesis. J. Pharmacol. Exp. Ther. 2007;320:274–280
  60. Suy K, Gijsenbergh F, Baute L. Emergency medical assistance during a mass gathering. Eur. J. Emerg. Med. 1999;6:249–254
  61. Tancer ME, Johanson CE, Freedman RR. MDMA elevates core temperature in warm and cold conditions in man. In: College on Problems of Drug Dependence Annual Conference. Florida, USA, June 2003. 2003;Conference Abstract, p. 169
  62. Topp L, Hando J, Dillon P, Roche A, Solowij N. Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend. 1999;55:105–115
  63. Vollenweider FX, Gamma A, Liechti M, Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naive healthy volunteers. Neuropsychopharmacology. 1998;19:241–251
  64. White SR. Amphetamine toxicity. Semin. Respir. Crit. Care Med. 2002;23:27–36
  65. Williams H, Dratcu L, Taylor R, Roberts M, Oyefeso A. Saturday night fever: ecstasy related problems in a London accident and emergency department. J. Acc. Emerg. Med. 1998;15:322–326
  66. Winstock AR, Griffiths P, Stewart D. Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend. 2001;64:9–17

PII: S0376-8716(11)00357-7

doi: 10.1016/j.drugalcdep.2011.08.012

Drug and Alcohol Dependence
Volume 121, Issue 1 , Pages 1-9 , 1 February 2012

Article Tools